Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 57077-57078 [E7-19685]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 193 / Friday, October 5, 2007 / Notices
that could result in cumulative
environmental impacts.
The NRC staff finds that the proposed
release of the Facility for unrestricted
use and the termination of the NRC
materials license is in compliance with
10 CFR 20.1402. Based on its review,
the staff considered the impact of the
residual radioactivity at the Facility and
concluded that the proposed action will
not have a significant effect on the
quality of the human environment.
Environmental Impacts of the
Alternatives to the Proposed Action
Due to the largely administrative
nature of the proposed action, its
environmental impacts are small.
Therefore, the only alternative the staff
considered is the no-action alternative,
under which the staff would leave
things as they are by simply denying the
amendment request. This no-action
alternative is not feasible because it
conflicts with 10 CFR 30.36(d),
requiring that decommissioning of
byproduct material facilities be
completed and approved by the NRC
after licensed activities cease. The
NRC’s analysis of the Licensee’s final
status survey data confirmed that the
Facility meets the requirements of 10
CFR 20.1402 for unrestricted release and
for license termination. Additionally,
denying the amendment request would
result in no change in current
environmental impacts. The
environmental impacts of the proposed
action and the no-action alternative are
therefore similar, and the no-action
alternative is accordingly not further
considered.
yshivers on PROD1PC62 with NOTICES
Conclusion
The NRC staff has concluded that the
proposed action is consistent with the
NRC’s unrestricted release criteria
specified in 10 CFR 20.1402. Because
the proposed action will not
significantly impact the quality of the
human environment, the NRC staff
concludes that the proposed action is
the preferred alternative.
Agencies and Persons Consulted
NRC provided a draft of this
Environmental Assessment to the
Connecticut Department of
Environmental Protection for review on
August 24, 2007. On September 18,
2007, State of Connecticut, Department
of Environmental Protection responded
by electronic mail. The State agreed
with the conclusions of the EA, and
otherwise had no comments.
The NRC staff has determined that the
proposed action is of a procedural
nature, and will not affect listed species
or critical habitat. Therefore, no further
VerDate Aug<31>2005
17:30 Oct 04, 2007
Jkt 214001
consultation is required under Section 7
of the Endangered Species Act. The
NRC staff has also determined that the
proposed action is not the type of
activity that has the potential to cause
effects on historic properties. Therefore,
no further consultation is required
under Section 106 of the National
Historic Preservation Act.
III. Finding of No Significant Impact
The NRC staff has prepared this EA in
support of the proposed action. On the
basis of this EA, the NRC finds that
there are no significant environmental
impacts from the proposed action, and
that preparation of an environmental
impact statement is not warranted.
Accordingly, the NRC has determined
that a Finding of No Significant Impact
is appropriate.
IV. Further Information
Documents related to this action,
including the application for license
amendment and supporting
documentation, are available
electronically at the NRC’s Electronic
Reading Room at https://www.nrc.gov/
reading-rm/adams.html. From this site,
you can access the NRC’s Agencywide
Document Access and Management
System (ADAMS), which provides text
and image files of NRC’s public
documents. The documents related to
this action are listed below, along with
their ADAMS accession numbers.
1. NUREG–1757, ‘‘Consolidated
NMSS Decommissioning Guidance’’;
2. Title 10 Code of Federal
Regulations, Part 20, Subpart E,
‘‘Radiological Criteria for License
Termination’’;
3. Title 10, Code of Federal
Regulations, Part 51, ‘‘Environmental
Protection Regulations for Domestic
Licensing and Related Regulatory
Functions’’;
4. NUREG–1496, ‘‘Generic
Environmental Impact Statement in
Support of Rulemaking on Radiological
Criteria for License Termination of NRCLicensed Nuclear Facilities’’;
5. Bayer Pharmaceuticals Corporation
Termination Request Letter dated April
17, 2007 [ML071150450];
6. Bayer Pharmaceuticals Corporation
Deficiency Response Letter dated July 9,
2007 [ML072180445]; and
7. Bayer Pharmaceuticals Corporation
Deficiency Response Letter dated
August 6, 2007 [ML072210116].
If you do not have access to ADAMS,
or if there are problems in accessing the
documents located in ADAMS, contact
the NRC Public Document Room (PDR)
Reference staff at 1–800–397–4209, 301–
415–4737, or by e-mail to pdr@nrc.gov.
These documents may also be viewed
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
57077
electronically on the public computers
located at the NRC’s PDR, O 1 F21, One
White Flint North, 11555 Rockville
Pike, Rockville, MD 20852. The PDR
reproduction contractor will copy
documents for a fee.
Dated at Region I, 475 Allendale Road,
King of Prussia this 28th day of September
2007.
For the Nuclear Regulatory Commission.
James P. Dwyer,
Chief, Commercial and R&D Branch, Division
of Nuclear Materials Safety, Region I.
[FR Doc. E7–19688 Filed 10–4–07; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of meeting.
AGENCY:
SUMMARY: NRC will convene a meeting
of the Advisory Committee on the
Medical Uses of Isotopes (ACMUI)
October 22–23, 2007. A sample of
agenda items to be discussed during the
public session includes: (1) NARM
legislation, transition plan, and
guidance; (2) status of specialty board
applications for NRC recognition; (3) Y–
90 microspheres guidance; (4) training
and experience implementation issues;
(4) recent security activities; (5)
potential changes to 10 CFR Part 35; (6)
licensing guidance for the Leksell
Gamma-Knife PerfexionTM; and (7)
review of recent medical events. A copy
of the agenda will be available at https://
www.nrc.gov/reading-rm/doccollections/acmui/agenda or by emailing Ms. Ashley M. Tull at the
contact information below.
Purpose: Discuss issues related to 10
CFR Part 35 Medical Use of Byproduct
Material.
Date and Time for Closed Sessions:
October 22, 2007, from 8 a.m. to 10 a.m.
This session will be closed so that NRC
staff and ACMUI can discuss Committee
business, which may include: Ethics
training, personnel information, and
other internal NRC issues.
Date and Time for Open Sessions:
October 22, 2007, from 10 a.m. to 5 p.m.
and October 23, 2007, from 8 a.m. to 5
p.m.
Address for Public Meeting: U.S.
Nuclear Regulatory Commission, Two
White Flint North Building, Room
T2B3, 11545 Rockville Pike, Rockville,
Maryland 20852.
Public Participation: Any member of
the public who wishes to participate in
E:\FR\FM\05OCN1.SGM
05OCN1
57078
Federal Register / Vol. 72, No. 193 / Friday, October 5, 2007 / Notices
the meeting should contact Ms. Tull
using the information below.
Contact Information: Ashley M. Tull,
e-mail: amt1@nrc.gov, telephone: (301)
415–5294 or (918) 488–0552.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the
meeting. Dr. Malmud will conduct the
meeting in a manner that will facilitate
the orderly conduct of business. The
following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Tull at the
contact information listed above. All
submittals must be received by October
17, 2007, and must pertain to the topic
on the agenda for the meeting.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the Chairman.
3. The transcript and written
comments will be available for
inspection on NRC’s web site (https://
www.nrc.gov) and at the NRC Public
Document Room, 11555 Rockville Pike,
Rockville, MD 20852–2738, telephone
(800) 397–4209, on or about January 23,
2008. Minutes of the meeting will be
available on or about December 7, 2007.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Tull of their
planned attendance.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in Title 10,
U.S. Code of Federal Regulations, part 7.
Dated at Rockville, Maryland this 1st day
of October 2007.
J. Samuel Walker,
Acting Secretary of the Commission.
[FR Doc. E7–19685 Filed 10–4–07; 8:45 am]
BILLING CODE 7590–01–P
RAILROAD RETIREMENT BOARD
yshivers on PROD1PC62 with NOTICES
Proposed Collection; Comment
Request
Summary: In accordance with the
requirement of Section 3506 (c)(2)(A) of
the Paperwork Reduction Act of 1995
which provides opportunity for public
comment on new or revised data
collections, the Railroad Retirement
Board (RRB) will publish periodic
summaries of proposed data collections.
Comments are invited on: (a) Whether
the proposed information collection is
necessary for the proper performance of
the functions of the agency, including
VerDate Aug<31>2005
15:33 Oct 04, 2007
Jkt 214001
whether the information has practical
utility; (b) the accuracy of the RRB’s
estimate of the burden of the collection
of the information; (c) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden related to
the collection of information on
respondents, including the use of
automated collection techniques or
other forms of information technology.
Title and purpose of information
collection: Report of Medicaid State
Office on Beneficiary’s Buy-In Status;
OMB 3220–0185.
Under Section 7(d) of the Railroad
Retirement Act, the RRB administers the
Medicare program for persons covered
by the railroad retirement system. Under
Section 1843 of the Social Security Act,
states may enter into ‘‘buy-in
agreements’’ with the Secretary of
Health and Human Services for the
purpose of enrolling certain groups of
low-income individuals under the
Medicare medical insurance (Part B)
program and paying the premiums for
their insurance coverage. Generally,
these individuals are categorically
needy under Medicaid and meet the
eligibility requirements for Medicare
Part B. States can also include in their
buy-in agreements, individuals who are
eligible for medical assistance only. The
RRB uses Form RL–380–F, Report to
State Medicaid Office, to obtain
information needed to determine if
certain railroad beneficiaries are entitled
to receive Supplementary Medical
Insurance program coverage under a
state buy-in agreement in states in
which they reside. Completion of Form
RL–380-F is voluntary. One response is
received from each respondent.
At the request of various state
Medicaid offices, the RRB proposes
revisions to Form RL–380-F to add
items requesting a beneficiary’s Part A
and Part B effective date. The new
information will assist them in locating
pertinent records of the subject
beneficiary. Other minor non-burden
impacting editorial changes are
proposed. The estimated completion
time for Form RL–380-F remains
unchanged at 10 minutes per response.
The RRB estimates that approximately
600 responses are received annually.
Additional Information or Comments:
To request more information or to
obtain a copy of the information
collection justification, forms, and/or
supporting material, please call the RRB
Clearance Officer at (312) 751–3363 or
send an e-mail request to
Charles.Mierzwa@RRB.GOV.
Comments regarding the information
collection should be addressed to
Ronald J. Hodapp, Railroad Retirement
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
Board, 844 North Rush Street, Chicago,
Illinois 60611–2092 or send an e-mail to
Ronald.Hodapp@RRB.GOV. Written
comments should be received within 60
days of this notice.
Charles Mierzwa,
Clearance Officer.
[FR Doc. E7–19709 Filed 10–4–07; 8:45 am]
BILLING CODE 7905–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–56559; File No. SR–CBOE–
2007–103]
Self-Regulatory Organizations;
Chicago Board Options Exchange,
Incorporated; Notice of Filing and
Order Granting Accelerated Approval
of Proposed Rule Change To Trade
Shares of the iShares FTSE/Xinhua
China 25 Index Fund Pursuant to
Unlisted Trading Privileges
September 27, 2007.
Pursuant to Section 19(b)(1) of the
Securities Exchange Act of 1934
(‘‘Act’’) 1 and Rule 19b–4 thereunder,2
notice is hereby given that on
September 6, 2007, the Chicago Board
Options Exchange, Incorporated
(‘‘CBOE’’ or ‘‘Exchange’’) filed with the
Securities and Exchange Commission
(‘‘Commission’’) the proposed rule
change as described in Items I and II
below, which Items have been
substantially prepared by the Exchange.
This order provides notice of the
proposed rule change and approves the
proposed rule change on an accelerated
basis.
I. Self-Regulatory Organization’s
Statement of the Terms of Substance of
the Proposed Rule Change
The Exchange proposes to trade on
the CBOE Stock Exchange (‘‘CBSX’’)
shares of the iShares FTSE/Xinhua
China 25 Index Fund (‘‘Fund’’) pursuant
to unlisted trading privileges (‘‘UTP’’).
The text of the proposed rule change is
available at CBOE, the Commission’s
Public Reference Room, and https://
www.cboe.org/legal.
II. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Change
In its filing with the Commission, the
Exchange included statements
concerning the purpose of and basis for
the proposed rule change and discussed
any comments it received on the
1 15
2 17
E:\FR\FM\05OCN1.SGM
U.S.C. 78s(b)(1).
CFR 240.19b–4.
05OCN1
]]>Agencies
[Federal Register Volume 72, Number 193 (Friday, October 5, 2007)]
[Notices]
[Pages 57077-57078]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-19685]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: NRC will convene a meeting of the Advisory Committee on the
Medical Uses of Isotopes (ACMUI) October 22-23, 2007. A sample of
agenda items to be discussed during the public session includes: (1)
NARM legislation, transition plan, and guidance; (2) status of
specialty board applications for NRC recognition; (3) Y-90 microspheres
guidance; (4) training and experience implementation issues; (4) recent
security activities; (5) potential changes to 10 CFR Part 35; (6)
licensing guidance for the Leksell Gamma-Knife[reg]
PerfexionTM; and (7) review of recent medical events. A copy
of the agenda will be available at https://www.nrc.gov/reading-rm/doc-
collections/acmui/agenda or by e-mailing Ms. Ashley M. Tull at the
contact information below.
Purpose: Discuss issues related to 10 CFR Part 35 Medical Use of
Byproduct Material.
Date and Time for Closed Sessions: October 22, 2007, from 8 a.m. to
10 a.m. This session will be closed so that NRC staff and ACMUI can
discuss Committee business, which may include: Ethics training,
personnel information, and other internal NRC issues.
Date and Time for Open Sessions: October 22, 2007, from 10 a.m. to
5 p.m. and October 23, 2007, from 8 a.m. to 5 p.m.
Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two
White Flint North Building, Room T2B3, 11545 Rockville Pike, Rockville,
Maryland 20852.
Public Participation: Any member of the public who wishes to
participate in
[[Page 57078]]
the meeting should contact Ms. Tull using the information below.
Contact Information: Ashley M. Tull, e-mail: amt1@nrc.gov,
telephone: (301) 415-5294 or (918) 488-0552.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the meeting. Dr. Malmud will
conduct the meeting in a manner that will facilitate the orderly
conduct of business. The following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a written statement should submit an
electronic copy to Ms. Tull at the contact information listed above.
All submittals must be received by October 17, 2007, and must pertain
to the topic on the agenda for the meeting.
2. Questions and comments from members of the public will be
permitted during the meeting, at the discretion of the Chairman.
3. The transcript and written comments will be available for
inspection on NRC's web site (https://www.nrc.gov) and at the NRC Public
Document Room, 11555 Rockville Pike, Rockville, MD 20852-2738,
telephone (800) 397-4209, on or about January 23, 2008. Minutes of the
meeting will be available on or about December 7, 2007.
4. Persons who require special services, such as those for the
hearing impaired, should notify Ms. Tull of their planned attendance.
This meeting will be held in accordance with the Atomic Energy Act
of 1954, as amended (primarily Section 161a); the Federal Advisory
Committee Act (5 U.S.C. App); and the Commission's regulations in Title
10, U.S. Code of Federal Regulations, part 7.
Dated at Rockville, Maryland this 1st day of October 2007.
J. Samuel Walker,
Acting Secretary of the Commission.
[FR Doc. E7-19685 Filed 10-4-07; 8:45 am]
BILLING CODE 7590-01-P
